A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies with Oligometastases, NCT01898962
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival.
In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.
MORE DETAILS ON THIS TRIAL
I1261 / Carter 2005-01 / NCT01898962
TRIAL AVAILABLE AT THE FOLLOWING LOCATIONS